Catalogo dei prodotti della ricerca

GUARINI, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.899
EU - Europa 3.104
AS - Asia 1.711
SA - Sud America 65
AF - Africa 57
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.843
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.831
SE - Svezia 977
IT - Italia 898
SG - Singapore 664
IN - India 545
CN - Cina 475
FI - Finlandia 307
UA - Ucraina 262
DE - Germania 221
RO - Romania 120
GB - Regno Unito 90
CA - Canada 63
BG - Bulgaria 56
AR - Argentina 55
IE - Irlanda 42
TG - Togo 40
BE - Belgio 25
GR - Grecia 24
FR - Francia 22
NL - Olanda 21
ZA - Sudafrica 11
CH - Svizzera 8
AT - Austria 7
BR - Brasile 6
AU - Australia 5
IL - Israele 5
MX - Messico 5
RS - Serbia 5
AL - Albania 4
CL - Cile 4
IR - Iran 4
RU - Federazione Russa 4
KZ - Kazakistan 3
SC - Seychelles 3
TR - Turchia 3
EG - Egitto 2
ES - Italia 2
EU - Europa 2
HK - Hong Kong 2
JP - Giappone 2
LT - Lituania 2
PH - Filippine 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KR - Corea 1
LI - Liechtenstein 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
SA - Arabia Saudita 1
Totale 14.843
Salva come PNG Salva come JPEG
Città #
Fairfield 1.640
Ashburn 732
Chandler 731
Woodbridge 688
Seattle 637
Wilmington 598
Houston 572
Cambridge 539
Singapore 447
Ann Arbor 366
Rome 346
Princeton 343
Beijing 328
Plano 265
San Paolo di Civitate 243
Boston 182
Lawrence 172
Dearborn 169
San Diego 113
Jacksonville 108
Millbury 101
Bremen 99
Stockholm 90
Des Moines 83
Andover 81
New York 69
Santa Clara 62
Sofia 55
Helsinki 52
Federal 51
Norwalk 51
Toronto 43
Dublin 42
Lomé 40
Southend 38
San Mateo 36
Boardman 34
Falls Church 27
Brussels 24
Hefei 20
Bühl 19
Florence 18
Nanjing 17
Mannheim 15
Milan 15
Kunming 14
Ottawa 12
Turin 11
Guangzhou 10
Redmond 10
Bologna 9
Naples 9
Fremont 8
Indiana 8
Auburn Hills 7
Fasano 7
Los Angeles 7
Paris 7
Phoenix 7
Pune 7
Buffalo 6
Laurel 6
London 6
Nanchang 6
Nuoro 6
Shenyang 6
Timisoara 6
Trento 6
Catania 5
Chengdu 5
Chieuti 5
Ercolano 5
Fuzhou 5
Jinan 5
Muizenberg 5
Redwood City 5
Vienna 5
Westminster 5
Cagliari 4
Council Bluffs 4
Lappeenranta 4
Montréal 4
Moscow 4
Prato 4
Sant'Agostino 4
Tehran 4
Tirana 4
Walsall 4
Washington 4
Zhengzhou 4
Casalnuovo di Napoli 3
Chicago 3
Chongqing 3
Crotone 3
Freiburg 3
Genoa 3
Gossolengo 3
Groningen 3
Mexico City 3
North York 3
Totale 10.710
Salva come PNG Salva come JPEG
Nome #
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. 137
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage 114
Clinical relevance of silent red blood cell autoantibodies. 112
Efficacy of rituximab treatment in postpartum acquired haemophilia A. 101
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial 101
Comparative analysis between RQ-PCR and digital-droplet-PCR of immunoglobulin/T-cell receptor gene rearrangements to monitor minimal residual disease in acute lymphoblastic leukaemia 98
Critical role of c-Myc in acute myeloid leukemia involving direct regulation of miR-26a and histone methyltransferase EZH2 94
Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukemia. 92
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain react 92
A case of late isolated ovarian relapse of acute lymphoblastic leukemia after an allogeneic stem cell transplant. 92
Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults 91
A LYMPHOTACTIN-PRODUCING MONOCLONAL T-CELL LYMPHOPROLIFERATIVE DISORDER WITH EXTREME LYMPHOCYTOPENIA AND PROGRESSIVE LEUKOENCEPHALOPATHY 86
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes 86
Production of tumor necrosis factor?alpha (TNF) by B?cell chronic lymphocytic leukemia cells. A possible regulatory role of TNF in the progression of the disease. 85
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug nutlin-3: a proposal for clinical application. 84
ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression 84
Spontaneous regression of chronic lymphocytic leukemia: Clinical and biologic features of 9 cases 83
Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223 83
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. 83
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 83
Clinical characteristics and outcome of patients with autoimmune hemolytic anemia (AIHA) uniformly defined as primary by a diagnostic work-up 83
Functional analysis and gene expression profile of umbilical cord blood regulatory T cells 83
Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features 82
Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease 82
Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma 82
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. 82
The interplay between the master transcription factor PU.1 and miR-424 regulates human monocyte/macrophage differentiation. 81
IL2 treatment for cancer: from biology to gene therapy. 80
Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. 80
Cytotoxic effectors activated by low-dose IL-2 plus IL-12 lyse IL-2 resistant autologous acute myeloid leukaemia blasts 79
An accurate and rapid flow cytometric diagnosis of BCR-ABL positive acute lymphoblastic leukemia 78
Clinical implications of the molecular genetics of chronic lymphocytic leukemia 78
BCR-ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. 78
Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. 76
Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease. 76
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. 75
13q14 Deletion Size and Number of Deleted Cells Both Influence Prognosis in Chronic Lymphocytic Leukemia 75
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile 75
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 75
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome. 75
Angiogenic activity in 1(g)V(H) mutated and unmutated chronic lymphocytic leukemia (CLL): Indications for the therapeutic use of VEGF-signaling inhibitors. 74
Protein Kinase Gene Expression Profiling and In Vitro Functional Experiments Identify Novel Potential Therapeutic Targets in Adult Acute Lymphoblastic Leukemia 74
Bendamustine in combination with Ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. 74
IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells 73
A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. 72
A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia? 72
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 72
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. 71
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib 71
ATM-ATR dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK cell susceptibility and is associated with a senescent phenotype 71
A broad and integrated diagnostic work-up for a modern management of acute lymphoblastic leukemia (ALL) 70
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 70
TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poorresponse to induction therapy. 70
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia 70
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 69
Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis 69
Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia 69
Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia 69
Characterization of B- and T-Lineage Acute Lymphoblastic Leukemia by Integrated Analysis of MicroRNA and mRNA Expression Profiles 69
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia 69
Whole-genome amplification for the detection of molecular targets and minimal residual disease monitoring in acute lymphoblastic leukaemia 68
null 68
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications 68
Minimal residual disease in acute lymphoblastic leukemia: technical and clinical advances 68
A SINGLE-ARM MULTI-CENTER TRIAL OF BENDAMUSTINE GIVEN WITH OFATUMUMAB (BENDOFA) IN PATIENTS WITH REFRACTORY OR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA. GIMEMA CLL0809 PROTOCOL 68
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 re-arrangement and the pre-B stage of differentiation, and prognostic implications. 68
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 67
INTERLEUKIN-2 GENE-TRANSDUCED HUMAN LEUKEMIC CELLS INDUCE MAJOR HISTOCOMPATIBILITY COMPLEX-RESTRICTED AND UNRESTRICTED ANTI-LEUKEMIC EFFECTORS IN MIXED LYMPHOCYTE-TUMOR CULTURES. 67
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 67
Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial 67
Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia 66
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. 66
Cytokines in B cell chronic lymphocytic leukemia. 66
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. 66
Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up succesfully treated with chemotherapy alone 65
Comorbidities and FLT3-ITD Abnormalities as Independent Prognostic Indicators of Survival in Elderly Acute Myeloid Leukaemia Patients 65
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy 65
Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors 65
null 64
Clinical responses in allografted acute leukaemia patients with resistant disease using a combined chemo-immunotherapeutic treatment strategy 64
NOTCH1 mutations in+12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of+12 CLL 64
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. 63
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders 63
NOTCH1, SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment 63
Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab 63
Thrombocytopenia in acute leukaemia patients treated with IL2: Cytolytic effect of LAK cells on megakaryocytic progenitors. 62
null 62
null 62
Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin 62
Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment 62
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocitic leukemia cells. 62
Histopathological and molecular features of persistent polyclonal B-cell lymphocytosis (PPBL) with progressive splenomegaly 61
IgV(H) germline and mutated chronic lymphocytic leukemia (CLL) cases exert a diverse responsiveness upon BCR ligation. 61
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation 61
Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission 61
Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients 60
The changing scene of adult acute lymphoblastic leukemia 60
Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatement in patients enrolled in the GIMEMA LAL 0496 protocol. 60
Acute promyelocytic leukemia: results of therapy and analysis of 13 cases. 60
New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia 60
Totale 7.434
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.598
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.881 0 0 23 164 344 463 471 402 368 347 188 111
2020/20211.001 111 157 41 84 41 49 35 126 118 116 94 29
2021/20223.366 26 176 270 392 423 81 64 309 222 256 506 641
2022/20233.012 628 671 186 313 282 352 35 201 223 16 77 28
2023/20241.269 85 201 51 87 86 163 41 86 12 141 159 157
2024/2025675 187 379 109 0 0 0 0 0 0 0 0 0
Totale 15.353